No biomarker
No biomarker
|
Merkel Cell Carcinoma
Merkel Cell Carcinoma
|
|
No biomarker
No biomarker
|
Merkel Cell Carcinoma
Merkel Cell Carcinoma
|
|
No biomarker
No biomarker
|
Merkel Cell Carcinoma
Merkel Cell Carcinoma
|
EP
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Merkel Cell Carcinoma
Merkel Cell Carcinoma
|
nivolumab
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Merkel Cell Carcinoma
Merkel Cell Carcinoma
|
cisplatin
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Merkel Cell Carcinoma
Merkel Cell Carcinoma
|
carboplatin
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Merkel Cell Carcinoma
Merkel Cell Carcinoma
|
carboplatin + etoposide oral
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Merkel Cell Carcinoma
Merkel Cell Carcinoma
|
topotecan
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Merkel Cell Carcinoma
Merkel Cell Carcinoma
|
CAV
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Merkel Cell Carcinoma
Merkel Cell Carcinoma
|
AST-008
Sensitive: B - Late Trials
|
ARID2 mutation
ARID2 mutation
|
Merkel Cell Carcinoma
Merkel Cell Carcinoma
|
Immunotherapy
Sensitive: C3 – Early Trials
|
NTRK1 mutation
NTRK1 mutation
|
Merkel Cell Carcinoma
Merkel Cell Carcinoma
|
Immunotherapy
Sensitive: C3 – Early Trials
|
PD-L1 expression
PD-L1 expression
|
Merkel Cell Carcinoma
Merkel Cell Carcinoma
|
avelumab
Sensitive: C3 – Early Trials
|
PD-1 expression
PD-1 expression
|
Merkel Cell Carcinoma
Merkel Cell Carcinoma
|
Immunotherapy
Sensitive: C3 – Early Trials
|
DLL3 expression
DLL3 expression
|
Merkel Cell Carcinoma
Merkel Cell Carcinoma
|
rovalpituzumab tesirine
Sensitive: C4 – Case Studies
|
PD-L1 negative
PD-L1 negative
|
Merkel Cell Carcinoma
Merkel Cell Carcinoma
|
avelumab
Sensitive: C4 – Case Studies
|
NCAM1 expression
NCAM1 expression
|
Merkel Cell Carcinoma
Merkel Cell Carcinoma
|
nivolumab
Sensitive: C4 – Case Studies
|
NKX2-1 expression
NKX2-1 expression
|
Merkel Cell Carcinoma
Merkel Cell Carcinoma
|
avelumab
Sensitive: C4 – Case Studies
|
